戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ger and substrate for atrial and ventricular proarrhythmia.
2 en withdrawn for their ability to cause such proarrhythmia.
3 nonfailing hearts and absence of ventricular proarrhythmia.
4 g to increased conduction in homogeneity and proarrhythmia.
5 titute an important mechanism of ventricular proarrhythmia.
6 e device longevity, and avoid device-induced proarrhythmia.
7  of non-PV foci are sufficient to treat this proarrhythmia.
8 ac abnormalities secondary to a high risk of proarrhythmia.
9 hythm disorders with an acceptable degree of proarrhythmia.
10  and should minimize the risk of ventricular proarrhythmia.
11 fficacy and/or carry the risk of ventricular proarrhythmia.
12 raindications and adverse effects, including proarrhythmia.
13  development of long-QT-mediated ventricular proarrhythmia.
14  may be futile or lead to atrial scarring or proarrhythmia.
15 antiarrhythmic drugs carries a high risk for proarrhythmias.
16 ions under which autonomic imbalance induces proarrhythmia and can be modified to prevent or inhibit
17 l mechanism for individual susceptibility to proarrhythmia and highlight the need for a new paradigm
18 stigate the relationship between CRT-induced proarrhythmia and LV lead location within scar.
19 en mainly by hospitalizations for arrhythmia/proarrhythmia and other cardiovascular causes, but not b
20                         However, the lack of proarrhythmia and the reduction in arrhythmic death supp
21 clinical consequences-arrhythmia recurrence, proarrhythmia, and death-that have now been reported in
22 s under which adverse event rates, including proarrhythmia, are expectedly low, would favor outpatien
23 nded for the evolving Comprehensive In Vitro Proarrhythmia Assay (CiPA) coordinated by the Health and
24                   The Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm provides lessons fro
25 ons obtained from the Comprehensive in vitro Proarrhythmia Assay initiative.
26             The CiPA (Comprehensive in vitro Proarrhythmia Assay) proposes to overcome these limitati
27                     RVP may have ventricular proarrhythmia because of competition of paced and intrin
28 infection, unnecessary shocks, potential for proarrhythmia, device malfunction, highly publicized man
29                            The occurrence of proarrhythmia did not correlate with ibutilide plasma co
30 s initial monitoring for QT prolongation and proarrhythmia, dronedarone does not.
31 anoelectrodes from being broadly adopted for proarrhythmia drug assessment.
32  scar was significantly more frequent in the proarrhythmia group (60% versus 9% P=0.03 on epicardial
33                                  Ventricular proarrhythmia hinders pharmacological atrial fibrillatio
34 aracterize cardiac sympathovagal balance and proarrhythmia in a canine model of PVC-CM.
35 rove and streamline regulatory assessment of proarrhythmia in preclinical drug development.
36                                 DZX-mediated proarrhythmia in T2DM was not related to changes in the
37                                  The risk of proarrhythmia is increased in patients with abnormal car
38 erter-defibrillators (ICDs), but ventricular proarrhythmia is less clear.
39                                 Drug-induced proarrhythmia is so tightly associated with prolongation
40 ng from intermittent inappropriate pacing to proarrhythmia leading to patient mortality.
41 review some methodologies employed to assess proarrhythmia liability of drugs, discuss the challenges
42 ized and/or excreted are the cornerstones of proarrhythmia management.
43 s associated with QT prolongation yet absent proarrhythmia markers for Torsade de Pointes (TdP).
44 rapamil, vanoxerine and bepridil produced no proarrhythmia markers.
45 tioned, particularly for sotalol, with which proarrhythmia may be dose related.
46 disease, for patients receiving a drug whose proarrhythmia may be idiosyncratic (e.g., quinidine), an
47 e the potential mechanism for the flecainide proarrhythmia observed in CAST, the voltage dependence o
48                     There was no ventricular proarrhythmia observed throughout the course of this stu
49                                  CRT-induced proarrhythmia occurred in 8 patients (12.5%).
50                                           No proarrhythmia occurred.
51 lying appropriate medical management without proarrhythmia or compromised ICD function.
52                                           No proarrhythmia or other negative effects were discernable
53 l storm (100% versus 39% of patients with no proarrhythmia; P<0.01), requiring temporary biventricula
54 atrial (p = 0.03) and ventricular (p = 0.03) proarrhythmia persisted.
55                                  CRT-induced proarrhythmia presented early with electrical storm and
56 diac resynchronization therapy (CRT)-induced proarrhythmia remains unknown.
57                              All ventricular proarrhythmia resulted from shocks delivered during the
58 on mechanisms underlying QT prolongation and proarrhythmia, risk factors, including the role of genet
59                                  The current proarrhythmia safety testing paradigm, although highly e
60 tial mechanistic basis for the novel form of proarrhythmia seen with this macrolide antibiotic.
61 pecific fashion, and the risk of ventricular proarrhythmia should be minimized.
62  cardiac action potential as an indicator of proarrhythmia, supposing that these shape changes might
63                                In a model of proarrhythmia, the dog with chronic atrioventricular blo
64 ses the new concepts of arrhythmogenesis and proarrhythmia; the long QT interval syndrome; newer, mor
65 ocyte action potentials, AF, and ventricular proarrhythmia, to determine the relationship between the
66                                           No proarrhythmia was observed and arrhythmia termination ca
67                   A low incidence of serious proarrhythmia was seen with the administration of ibutil
68                               No significant proarrhythmias were noted.
69 dy provides mechanistic insights into atrial proarrhythmia with SQT3 Kir2.1 mutations and highlights